Strategy
The company acquired a next-generation oncolytic virus from IconOVir that it plans to develop as a locally administered therapy for bladder cancer.
Amylin analogs could well match the weight loss seen with Novo Nordisk and Eli Lilly’s GLP-1-based blockbusters with less fewer tolerability issues. The Danish company believes petrelintide will lead the pack and is vetting potential big pharma partners very carefully.
INFOGRAPHIC: 2024 was a particularly quiet year for biopharma M&A, with no buyouts reaching the $5bn threshold, while alliance volume and valuations declined compared to 2023, as well.
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.
The Swedish biotech has held positive talks with US regulators about the Phase III design for its pancreatic cancer candidate, mitazalimab. Now it needs to pin down a partner.
The Swedish company is celebrating approval for the first treatment for MCT8 deficiency
President Trump's Executive Order creating the commission does not mention vaccines, which Kennedy has criticized.
CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
The Paris-headquartered group has been reflecting on a solid performance last year.
Only two drugs have been approved for the progressive fibrosing interstitial lung disease but the pipeline is full of promising, and hopefully more tolerable, candidates.
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
Large headcount reduction and ending preclinical programs may give Inventiva runway to report Phase III data for lanifibranor that are expected during the second half of 2026.
The Swiss major may have to pay over $3bn for the dual-acting Factor XI/XIa inhibitor that it originally developed before the drug was passed on to Anthos Therapeutics, founded by private equity firm Blackstone and the Swiss major in 2019.
A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26
CEO Christopher Viehbacher has said repeatedly that Biogen will build its pipeline internally and through deals, and Grogan reshuffled the research organization with that in mind.
Dr Reddy’s hopes to be the “first one in the pack”, when Ozempic loses patent cover next year in markets like Canada, where the semaglutide opportunity is projected at $2bn. Openings for the product in 80 smaller markets also loom, it said, but the GLP-1 agonist won’t ‘replace’ generic Revlimid and all business levers will have to grow.
A Zydus-Takeda joint venture is expected to supply more raw materials to the Japanese major. Meanwhile, a tie-up with CVS Caremark for the sitagliptin franchise is a boost for Zydus’s US sales while the company focuses R&D efforts on rare diseases like ALS and CAPS
Relmada has acquired sepranolone, a potential blockbuster for the complex neurological condition characterized by involuntary tics, for a bargain €3m from the Stockholm group that went into liquidation late last year.
Mounjaro and Zepbound led Lilly’s 45% sales increase, but non-incretin products such as Verzenio and Taltz helped produce 20% growth outside of the incretin portfolio.